IMELDA RUSSELL: Open Payments
NPI 1528163540 · RIVERDALE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$432 in 22 payments from 8 companies in 2025. Trend: 2023 $981 · 2024 $145 · 2025 $432
Food & beverage: $432
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 10 | $155 |
| ABBVIE INC. | 5 | $113 |
| Merck Sharp & Dohme LLC | 2 | $38 |
| Aimmune Therapeutics, Inc. | 1 | $32 |
| Astellas Pharma US Inc | 1 | $29 |
| Shionogi Inc | 1 | $23 |
| Melinta Therapeutics, LLC | 1 | $22 |
| Theratechnologies Inc. | 1 | $21 |
Products named: DALVANCE, EMBLAVEO, ZERBAXA, ZENPEP, Cresemba, Fetroja, Rezzayo, EGRIFTA.
Industry payments across MD — which companies pay providers there.
